… Time to PD is measured from the start of first-line bevacizumab treatment to first PD; … of
first-line treatment to death. (B) Disposition of patients enrolled on the BRiTE study: 508 patients …

… ) in patients with metastatic colorectal cancer (mCRC) treated with first‑line bevacizumab plus
… were considered to be predictive markers of the therapeutic efficacy of bevacizumab. The …

… outcomes. In this review we discuss putative clinical, radiological, and molecular markers of
bevacizumab … compared with continued therapy without bevacizumab in colorectal cancer. …

… find any correlation between RRs of high-grade hypertension and OS (… hypertension may be
not correlated with clinical outcome for … as first-line therapy in metastatic colorectal cancer: a …

… for outcome analyses in less-selected, real-world patient … evaluate treatment patterns and
clinical outcomes in patients … treated in the first-line setting with FOLFOX–bevacizumab or …

… that bevacizumab induced arterial hypertension may correlate with the clinical outcome in
colorectal cancer patients [9] … The first line combination chemotherapy in our institution is either …

… treated with first-line therapy with FOLFIRI and bevacizumab or … of 228 patients receiving
FOLFIRI and bevacizumab (TRIBE) … demonstrate an even stronger correlation between G allele …

… Bevacizumab was administered as a first-line of treatment in 70.5 % of our … [35], there was
no significant correlation between the expression of NOTCH1 or DLL4 and VEGFR2. While …

… % in colorectal cancer patients treated with first-line chemotherapy (… in colorectal cancer
patients treated with bevacizumab. … ) Correlation of hypertension and proteinuria with outcome in …

… lung cancer, colorectal cancer, or ovarian cancer receiving … for developing
bevacizumab‐associated hypertension appears … was strongly correlated with the occurrence of …